SAMUEL COLLIER: Open Payments
NPI 1508064114 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,188 in 33 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,188
Food & beverage: $1,116Travel & lodging: $1,072
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $1,551 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $113 |
| E.R. Squibb & Sons, L.L.C. | 5 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| Janssen Pharmaceuticals, Inc | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: REXULTI, COBENFY, CAPLYTA, INVEGA SUSTENNA, AUSTEDO XR, INGREZZA, FANAPT.
Industry payments across TX — which companies pay providers there.
